CA-ARIBIO-CO.,-LTD.
31.3.2023 18:01:37 CEST | Business Wire | Press release
AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins.
The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States.
Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatment in a post-hoc analysis, including a dose dependent decline of pTau181 at 26 weeks, and further declines after 52 weeks of treatment. Patients randomized to 10 and 30 mg AR1001 treatment after 26 weeks of treatment with placebo also demonstrated similar declines in pTau181. Other plasma markers including NfL, GFAP and AB42/40 ratio were also measured but showed minimal change or no statistical differences over baseline levels.
AriBio initiated a phase 3 pivotal trial with 30mg of AR1001 to be administered daily to early and mild Alzheimer’s disease patients in December of 2022. Enrollment is expected to continue through 2024. “This biomarker data helps bolster the positive effects seen in cognition with the high dose of AR1001 in the Phase 2 study in mild AD patients. We will continue to collect both CSF and plasma as part of the phase 3 study to analyze as supportive data,” stated Dr. Greeley.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer’s disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HELLENiQ ENERGY and Chevron Sign Offshore Concession Agreements for Hydrocarbon Exploration and Production with the Hellenic Republic16.2.2026 19:07:00 CET | Press release
Marking a New Milestone in HELLENiQ ENERGY’s Upstream Portfolio HELLENiQ ENERGY, in collaboration with Chevron, signed today the Lease Agreements with the Hellenic Republic for the exploration of four offshore blocks located south of Crete and the Peloponnese, marking a significant milestone for Greece’s upstream development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216381183/en/ Snapshot from the signing of the lease agreements at the Maximos Mansion, attended by Prime Minister Kyriakos Mitsotakis. From left: Stavros Papastavrou, Minister of Environment and Energy; Andreas Shiamishis, CEO of HELLENiQ ENERGY; Gavin Lewis, VP Global New Ventures at Chevron; and Aristofanis Stefatos, CEO of HEREMA The successful consortium, with Chevron at 70% interest and being the Operator and HELLENiQ ENERGY at 30% interest, was selected following a competitive international tender launched by the Greek State in 2025. The four offs
Nexo Returns to the U.S.16.2.2026 17:00:00 CET | Press release
Nexo is relaunching its flagship Yield, Exchange, Loyalty, and Credit Lines in the United States. Nexo today announced its formal return to the United States market in 2026. The company’s official U.S. relaunch is being executed in partnership with regulated partners, providing a U.S.-compliant framework for the company’s investment and credit product offerings. Digital asset trading infrastructure is provided by Bakkt, a publicly listed U.S.-based digital asset platform purpose-built to support institutional risk management and compliance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216234514/en/ Nexo is relaunching its flagship Yield, Exchange, Loyalty, and Credit Lines in the United States. Nexo’s renewed presence in the United States follows a period of deliberate recalibration and reflects the company’s long-term commitment to operating in markets where regulatory frameworks are evolving, institutional standards a
TRU Simulation’s Full Flight Simulator for the Cessna Citation Ascend Achieves FAA Qualification, Expanding Advanced Training for Midsize Jet Pilots16.2.2026 16:00:00 CET | Press release
TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation, announced today its Full Flight Simulator (FFS) for the Cessna Citation Ascend has achieved Federal Aviation Administration (FAA) Level D qualification. This milestone significantly enhances advanced training options for midsize jet pilots, delivering a highly immersive and true-to-life training environment on the recently FAA certified Citation Ascend. European Union Aviation Safety Agency (EASA) qualification is anticipated in 2026, further extending the simulator’s global reach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216456292/en/ TRU Simulation’s Full Flight Simulator for the Cessna Citation Ascend achieves FAA qualification, expanding advanced training for midsize jet pilots “Pilots deserve training capabilities that reflect the advanced technology and performance that the Citation Ascend brings to the mid
AIT Worldwide Logistics Announces Strategic Partnership With Greenbriar Equity Group16.2.2026 15:03:00 CET | Press release
Agreement supports continuity, accelerating next phase of AIT’s growth plan Supply chain solutions leader AIT Worldwide Logistics (“AIT”) has entered into a definitive agreement to partner with Greenbriar Equity Group, L.P. (“Greenbriar”) in support of the global freight forwarder’s next chapter of growth. Financial terms of the private transaction were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216984391/en/ AIT Worldwide Logistics' strategic partnership with Greenbriar Equity Group represents one of the largest private acquisitions ever in the global freight forwarding sector. The deal marks the culmination of five successful years with The Jordan Company, L.P. (“TJC”). TJC, alongside key members of AIT’s executive leadership team, will remain invested in the company. Over the course of the company’s relationship with TJC, AIT has dramatically expanded its global footprint, acquired 14 businesses, and
Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials16.2.2026 14:00:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The company will be disclosing new clinical data from Part A and Part B from COMP005 and Part A from COMP006. The results are scheduled for release on February 17th at 6:30 am ET, followed by a webinar hosted by Compass management at 8:00 am ET. Live Webcast Compass management will host a live audio webcast on February 17th at 8:00 am ET. The webcast will be accessible at this link: https://lifescievents.com/event/hz02j0rpw/ A replay of the webcast will be accessible for 30 days following the event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom